Related Experiment Video
Updated: Sep 9, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent
Eric C Burton1, Erin Walker2, Lisa Boris1
1Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Background:
LB100 is a protein phosphatase 2A (PP2A) inhibitor. Glioma models show inhibition of PP2A by LB100 causes cell death. Whether LB100 crosses the human blood brain barrier (BBB) is unknown. We sought to determine the pharmacokinetic (PK) properties of LB100 in human subject gliomas.
Methods:
A two-stage, phase 0 trial was done. Eligibility required a recurrent adult diffuse type of glioma deemed surgically resectable. In the first stage, 5 patients were pre-surgically dosed with LB100. Resected tumor then underwent PK analysis by LC-MS/MS. If one of five tumors demonstrated a PK response three additional subjects would be enrolled. Pharmacokinetic effect would be declared significant if at least 2 of 8 patients demonstrated a PK response and pharmacodynamic studies would then be performed.
Results:
Five patients were evaluable. Glioblastoma, (n=2), Astrocytoma IDH-mutant grade 3- 4 (n=2), and Oligodendroglioma IDH-mutant, grade 2 (n=1). Mean Cmax was 146 ng/mL (range: 95-179 ng/mL). Mean plasma half-life (T1/2) was 1.2 hours (range: 1.09-1.46 hours). Mean plasma drug exposure (AUCINF) was 414 hr*ng/mL (range: 325 to 468 ng*hr/mL. Average concentration of LB100 in tumor was 0.19 nM (range: 0 to 0.67 nM). Average plasma concentration of LB100 was 77.26 nM (range: 30.81 to 132.26 nM). The percent of drug penetration into the brain was 0.31% (range: 0% to 1.04%). The IC50 of PP2A is 0.2-0.4 uM; showing drug penetration was inadequate.
Conclusion:
In this first PK analysis of LB100 in human gliomas there was poor penetration of LB100 into glial tumors.
